File TM, Alexander E, Goldberg L, et al. - Utilizing pooled Lefamulin Evaluation Against Pneumonia (LEAP) 1/2 data, researchers sought to explore lefamulin effectiveness/safety overall and within subgroups of patients presenting with comorbidities typical in community-acquired bacterial pneumonia (CABP) management. Adults with CABP in LEAP 1 were randomized to receive intravenous lefamulin (150 mg every 12 h) for 5‒7 days or moxifloxacin (400 mg every 24 h) for 7 days, with an optional intravenous-to-oral switch if predefined improvement criteria were met, whereas adults with CABP in LEAP 2 were randomized to receive oral lefamulin (600 mg every 12 h) for 5 days or moxifloxacin (400 mg every 24 h) for 7 days. Lefamulin may be a valuable intravenous/oral monotherapy alternative to fluoroquinolones or macrolides for the empiric treatment of CABP patients, including those at risk of poor outcomes due to age or other comorbidities.